TScan Therapeutics annual return on equity
2021
2022
2023
2024
2025
TScan Therapeutics Return on Equity (ROE) Growth & History (TCRX)
TScan Therapeutics's return on equity was −71.28% for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −71.28% | −6.20 pp |
| 2024 | 2024-12-31 | −65.08% | +6.21 pp |
| 2023 | 2023-12-31 | −71.29% | −20.39 pp |
| 2022 | 2022-12-31 | −50.90% | +31.30 pp |
| 2021 | 2021-12-31 | −82.20% | — |
TScan Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −36.59% | −17.49 pp |
| Q1 2026 | 2026-03-31 | −26.05% | −10.93 pp |
| Q4 2025 | 2025-12-31 | −17.20% | −1.97 pp |
| Q3 2025 | 2025-09-30 | −22.27% | −9.93 pp |
| Q2 2025 | 2025-06-30 | −19.10% | −2.36 pp |
| Q1 2025 | 2025-03-31 | −15.13% | +6.89 pp |
| Q4 2024 | 2024-12-31 | −15.24% | −2.97 pp |
| Q3 2024 | 2024-09-30 | −12.34% | +0.45 pp |
| Q2 2024 | 2024-06-30 | −16.74% | +1.16 pp |
| Q1 2024 | 2024-03-31 | −22.01% | +3.42 pp |
| Q4 2023 | 2023-12-31 | −12.26% | +5.06 pp |
| Q3 2023 | 2023-09-30 | −12.79% | +0.29 pp |
| Q2 2023 | 2023-06-30 | −17.90% | −7.02 pp |
| Q1 2023 | 2023-03-31 | −25.43% | −14.89 pp |
| Q4 2022 | 2022-12-31 | −17.33% | −8.85 pp |
| Q3 2022 | 2022-09-30 | −13.08% | +14.69 pp |
| Q2 2022 | 2022-06-30 | −10.89% | — |
| Q1 2022 | 2022-03-31 | −10.54% | — |
| Q4 2021 | 2021-12-31 | −8.48% | — |
| Q3 2021 | 2021-09-30 | −27.78% | — |
TScan Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, TScan Therapeutics's return on equity increased from −82.20% to −71.28%, a change of +10.91 percentage points. The latest reported quarter, Q2 2026, shows −36.59%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗